I hope this issue of the Journal finds you productive and well. I think you will enjoy the wide selection of papers that are in the issue.
lection of papers that are in the issue.
Over the last decade there have been a number of reports on the utility of the dexamethasone suppression test (DST) as an aid in the differential diagnosis of depression in elderly demented patients. In a comprehensive review article, Stacy Skare and Drs Becky Pew and Maurice Dysken review this confusing literature and conclude that the data do not support the use of the DST in discriminating between depression and dementia or between dementia subtypes ; the abnormal DST rate in demented patients was not significantly different from the abnormal DST rate in depressed patients. This finding is what many have suspected, and it is nice to have such a thorough review before us. The paper by Dr Tate-Ostroff and colleagues of Harvard Medical School presents their exciting and innovative work on the manner in which certain amyloid proteins are deposited into the senile plaques in brains of patients with Alzheimer's disease. It seems clear to me that at present there is little that clinicians or clinical researchers can do to slow the relentless progress of cognitive decline in patients with dementing illnesses and that research into the basic mechanisms of the illnesses, such as that presented here, is where the action is. It is likely that more innovative and successful therapies will arise once we have a better understanding of the basic pathophysiology and neurobiology of these illnesses. Dr Tate-&reg;stroff's group continues to make strides in this complex and important area.
Reflecting the increasing recognition by clinicians of the efficacy and safety of psychostimulant medications in the elderly, we have two papers in this issue that discuss their use in geriatric patients. There has been abundant hysteria (which even involved reluctance to publish scientific papers) concerning the use of these medications in the recent past, and it is heartening to see experienced geriatricians reporting careful documentation of the effects of these often helpful medications. Drs Patricia Pickett, Prakash Masand, and George Murray of the Psychiatric Consultation Service at Massachusetts General Hospital and Harvard Medical School present a comprehensive view of the literature and their own evaluation of 129 medically ill geriatric inpatients who received dextroamphetamine or methylphenidate for secondary depressive symptoms. By nonblind assessment, over 80% demonstrated some improvement, and over 65% experienced marked to moderate amelioration of their affective symptoms.
In only 8% of the patients were side effects serious enough to warrant termination of the psychostimulant trial. This is the first large review of these medications in a geriatric population. Drs Bennett Gurian and Erlene Rosowsky of Massachusetts Mental Health Center and also of Harvard Medical School discuss two elderly patients (one now age 105 years) who responded to methylphenidate and were maintained on the drug for extended periods. Both patients had sustained effects, and tolerance and toxicity did not develop. These authors also suggest that smaller dosages of this agent than previously recommended may be adequate in very old patients.
Dr Ira Katz and colleagues from the Medical College of Pennsylvania and the Philadelphia Geriatric Continued on page 162
